Filtered By:
Cancer: Lymphoma
This page shows you your search results in order of date. This is page number 16.
Order by Relevance | Date
Total 25227 results found since Jan 2013.
A case of Hodgkin lymphoma-type Richter syndrome presenting as small-intestinal perforation
Int J Hematol. 2023 Sep 6. doi: 10.1007/s12185-023-03655-2. Online ahead of print.ABSTRACTHodgkin lymphoma type of Richter syndrome (HL-type RS) is a rare disease that arises in patients with chronic lymphocytic leukemia (CLL). HL-type RS lesions can manifest in various sites and are often accompanied by related symptoms. This is the first case report to describe diagnosis of HL-type RS after emergency surgery for gastrointestinal perforation caused by the development of a HL-type RS lesion. A 47-year-old man diagnosed with CLL three years prior began treatment with ibrutinib due to worsening anemia and splenomegaly two mo...
Source: International Journal of Hematology - September 6, 2023 Category: Hematology Authors: Kosuke Miki Reiki Ogasawara Shunsuke Sugimura Junichi Sugita Rintaro Nozu Keisuke Kojima Daisuke Hidaka Ai Shimizu Kohei Okada Naoki Kobayashi Masahiro Ogasawara Masahiro Imamura Yoshihiro Matsuno Shuichi Ota Source Type: research
The Upregulation of miR-22 alleviates oxygen-glucose deprivation/reperfusion-induced injury by targeting Tiam1 in SH-SY5Y cells
In this study, we evaluated whether miR-22 participates in I/R-induced neuronal injury and the potential mechanism by using an oxygen-glucose deprivation/reperfusion (OGD/R) model in vitro. Our results showed that miR-22 was significantly down-regulated in SH-SY5Y cells suffering from OGD/R. Up-regulation of miR-22 by its specific mimic could protect SH-SY5Y cells against OGD/R-induced injury. The luciferase reporter assay demonstrated that T-cell lymphoma invasion and metastasis 1 (Tiam1) was a direct target of miR-22. MiR-22 mimic obviously inhibited Tiam1 expression in OGD/R-exposed SH-SY5Y cells. Tiam1 siRNA could atte...
Source: Acta Biochim Pol - September 6, 2023 Category: Biochemistry Authors: Jiansong Yin Yu Wan Jing Wang Mei Xue Source Type: research
Oncogenic viral DNA related to human breast cancer found on cattle milk and meat
Comp Immunol Microbiol Infect Dis. 2023 Aug 27;101:102053. doi: 10.1016/j.cimid.2023.102053. Online ahead of print.ABSTRACTBovine leukemia virus (BLV) is a major cause of lymphoma in cattle and has been recently correlated to breast cancer in humans. How and whether BLV might reach humans remains unknown but it could be through cattle-derived milk and meat. Here our aim was to investigate whether BLV DNA could be found in fresh milk and raw meat destined to human consumption and whether anti-BLV antibodies could be detected in human blood at the same geographical region. Milk (n = 36) and meat (n = 54) samples were collect...
Source: Comparative immunology, microbiology and infectious diseases. - September 6, 2023 Category: Allergy & Immunology Authors: Daniel Lazzari de Quadros Vitoria Agnoletto Ribeiro Mariana Antunes Rezende Yasmin Ampese Mat é M árcio Alexandro Gomes Katia Secchi Daisy Maria Strottmann Rafael Frandoloso Luiz Carlos Kreutz Source Type: research
Phase 1 Dose Escalation and Expansion Study of Golidocitinib, a Highly Selective JAK1 Inhibitor, in Relapsed or Refractory Peripheral T Cell Lymphomas
CONCLUSIONS: In this phase 1 study, golidocitinib demonstrated an acceptable safety profile and encouraging antitumor efficacy in heavily pre-treated patients with r/r PTCLs. These results support the initiation of the multinational pivotal study in patients with r/r PTCLs.PMID:37673210 | DOI:10.1016/j.annonc.2023.08.013
Source: Ann Oncol - September 6, 2023 Category: Cancer & Oncology Authors: Y Song D H Yoon H Yang J Cao D Ji Y Koh H Jing H Eom J Kwak W Lee J Lee H Shin J Jin M Wang Z Yang W Kim J Zhu Source Type: research
Design, synthesis and bioactivity evaluation of selenium-containing PI3K δ inhibitors
In conclusion, the Se-containing compound Se15 bearing pyrido[3,2-d]pyrimidine scaffold is a novel potent and selective PI3Kδ inhibitor. The introduction of selenium can enrich the structure of PI3Kδ inhibitors and provide a new idea for design of novel PI3Kδ inhibitors.PMID:37672953 | DOI:10.1016/j.bioorg.2023.106815
Source: Bioorganic Chemistry - September 6, 2023 Category: Chemistry Authors: Li Gao Hongyan Chuai Mengyan Ma San-Qi Zhang Jiye Zhang Jiyu Li Yang Wang Minhang Xin Source Type: research
A case of Hodgkin lymphoma-type Richter syndrome presenting as small-intestinal perforation
Int J Hematol. 2023 Sep 6. doi: 10.1007/s12185-023-03655-2. Online ahead of print.ABSTRACTHodgkin lymphoma type of Richter syndrome (HL-type RS) is a rare disease that arises in patients with chronic lymphocytic leukemia (CLL). HL-type RS lesions can manifest in various sites and are often accompanied by related symptoms. This is the first case report to describe diagnosis of HL-type RS after emergency surgery for gastrointestinal perforation caused by the development of a HL-type RS lesion. A 47-year-old man diagnosed with CLL three years prior began treatment with ibrutinib due to worsening anemia and splenomegaly two mo...
Source: International Journal of Hematology - September 6, 2023 Category: Hematology Authors: Kosuke Miki Reiki Ogasawara Shunsuke Sugimura Junichi Sugita Rintaro Nozu Keisuke Kojima Daisuke Hidaka Ai Shimizu Kohei Okada Naoki Kobayashi Masahiro Ogasawara Masahiro Imamura Yoshihiro Matsuno Shuichi Ota Source Type: research
HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic γδ T-cell Lymphoma
Cell Transplant. 2023 Jan-Dec;32:9636897231194265. doi: 10.1177/09636897231194265.ABSTRACTWhile chimeric antigen receptor (CAR)-T-cell therapy has demonstrated remarkable effectiveness in the treatment of B-cell lymphomas and leukemias, research on T-cell malignancies is still limited. Here, we reported a patient with hepatosplenic γδ T-cell lymphoma refractory to multiple lines of chemotherapy, who eventually achieved first complete remission with flow cytometry-confirmed minimal residual disease negativity after human leukocyte antigen (HLA) fully-mismatched sibling-derived CD7 CAR-T therapy. However, given the allogen...
Source: Cell Transplantation - September 5, 2023 Category: Cytology Authors: Xueer Xu Cheng Zu Mingming Zhang Pingnan Xiao Ruimin Hong Jingjing Feng Huijun Xu Jiazhen Cui Jian Yu Jimin Shi Guoqing Wei Alex H Chang He Huang Yongxian Hu Source Type: research
A pathogenic germline BRCA1 mutation identified in a patient with non-Hodgkin lymphoma and rectum adenocarcinoma: "Non-classical" hereditary cancer?
Asian J Surg. 2023 Sep 1:S1015-9584(23)01302-7. doi: 10.1016/j.asjsur.2023.08.134. Online ahead of print.NO ABSTRACTPMID:37661479 | DOI:10.1016/j.asjsur.2023.08.134
Source: Asian Journal of Surgery - September 4, 2023 Category: Surgery Authors: You Zhou Yanjie Xu Jiemin Zhao Wenwei Hu Source Type: research
CDK9 Inhibitor Induces Apoptosis, Autophagy, and Suppression of Tumor Growth in Adult T-Cell Leukemia/Lymphoma
Biol Pharm Bull. 2023;46(9):1269-1276. doi: 10.1248/bpb.b23-00228.ABSTRACTAdult T-cell leukemia/lymphoma (ATL) is a hematopoietic malignancy with a poor prognosis that develops in approximately 5% of human T-cell leukemia virus type 1 (HTLV-1) carriers. Cyclin-dependent kinase 9 (CDK9), together with Cyclin T, forms a transcription elongation factor, positive transcription elongation factor b (P-TEFb). P-TEFb promotes transcriptional elongation by phosphorylating the second serine (Ser2) of the seven amino acid repeat sequence in the C-terminal domain of RNA polymerase II (RNAP II). CDK9 inhibitors suppress cell proliferat...
Source: Biological and Pharmaceutical Bulletin - September 4, 2023 Category: Drugs & Pharmacology Authors: Naho Kato Tomohiro Kozako Takeo Ohsugi Yuichiro Uchida Makoto Yoshimitsu Kenji Ishitsuka Akiyoshi Aikawa Shin-Ichiro Honda Source Type: research
SOHO State of the Art Updates and Next Questions | Immunotherapeutic Options for Patients With Mantle Cell Lymphoma Who Progress on BTK Inhibitors
Clin Lymphoma Myeloma Leuk. 2023 Aug 14:S2152-2650(23)00258-6. doi: 10.1016/j.clml.2023.08.011. Online ahead of print.ABSTRACTMantle cell lymphoma is a challenging subtype of B-cell non-Hodgkin lymphoma treat characterized by its aggressive nature and propensity for relapse or refractory (R/R) disease for many patients. The introduction of Bruton's tyrosine kinase inhibitors has significantly improved the outcomes for patients with R/R MCL, but a considerable proportion of patients eventually experience disease progression or develop resistance to these agents. In recent years, immunotherapeutic approaches have emerged as ...
Source: Clinical Lymphoma and Myeloma - September 4, 2023 Category: Cancer & Oncology Authors: Rahul K Nayak Drew Gerber Chen Zhang Jonathon B Cohen Source Type: research
Ultrasonographic findings of multicentric malignant lymphoma involving the urinary bladder in a dog: Diagnosis and monitoring during chemotherapy
Can Vet J. 2023 Sep;64(9):844-848.ABSTRACTA 5.5-year-old spayed female cane corso dog was presented for recurrent hematuria and dysuria. Abdominal ultrasound demonstrated severe hypoechoic urinary bladder wall thickening with irregular mucosal surface and polypoid-like lesions protruding into the lumen, abdominal polyadenomegaly, and splenic honeycombing. High-grade lymphoma was diagnosed on urinary bladder wall cytology. Clinical signs and ultrasonographic findings initially improved following a modified CHOP-based chemotherapy protocol, but the multicentric lymphoma then progressed with thoracic spread, leading to the do...
Source: The Canadian Veterinary Journal - September 4, 2023 Category: Veterinary Research Authors: Antonin Martenne-Duplan Cindy Chervier Marl ène Finck Source Type: research
Lisocabtagene maraleucel CAR-T cells - second line treatment in patients with relapsed or refractory large B cell lymphoma
Bull Cancer. 2023 Sep 1:S0007-4551(23)00334-X. doi: 10.1016/j.bulcan.2023.06.010. Online ahead of print.NO ABSTRACTPMID:37661551 | DOI:10.1016/j.bulcan.2023.06.010
Source: Bulletin du Cancer - September 4, 2023 Category: Cancer & Oncology Authors: Mathilde Chanut Charles Herbaux Source Type: research
